Abstract Library

#4377 Characteristics of endoscopic ultrasonography in patients with gastrointestinal and pancreatic neuroendocrine tumours

Introduction: Neuroendocrine tumours are most commonly found in the gastrointestinal tract. With the development of endoscopic ultrasound, the incidence of GEP-NENs has increased year by year.

Conference:

Presenting Author:

Authors: Dai C, Tang Y, Liu G, Zhu Y, Tu R,

Keywords: gastroenteropancreatic neuroendocrine tumour, endoscopic ultrasound, characteristics,

#3855 Contrast-enhanced and tissue harmonic endoscopic ultrasound for pancreatic neuroendocrine tumor diagnostic

Introduction: Endoscopic ultrasonography (EUS) is an examination using ultrasound and an endoscopic device, designed to image digestive tract and adjacent organs. The combination of tissue harmonic endoscopic imaging (THI) and contrast enhancement (CE) expands its diagnostic and imaging capabilities.

Conference:

Presenting Author:

Authors: Uhrík P, Nosakova L, Kalman M, Bánovčin P,

Keywords: pancreatic, neuroendocrine, tumor, endoscopic, ultrasound, contrast, enhancement,

#3551 Endoscopic ultrasonography and elastography in pancreatic and gastrointestinal neuroendocrine tumors diagnostic

Introduction: Endoscopic ultrasonography (EUS) is an examination using ultrasound and an endoscopic device, designed to image digestive tract and adjacent organs. The combination of EUS and elastography (EG) expands diagnostic and imaging capabilities.

Conference:

Presenting Author: Uhrík P

Authors: Uhrík P, Nosakova L, Pindura M, Miklušica J, Bánovčin P,

Keywords: pancreatic, gastrointestinal, neuroendocrine tumor, endoscopic ultrasound, elastography,

#3482 PANDORA-2 protocol - Intervention study to improve quality of life in patients with small (≤2 cm) non-functional pancreatic neuroendocrine tumors

Introduction: Current guidelines changed the treatment strategy for small (≤2cm) non-functioning pancreatic neuroendocrine tumors (NF-pNET) from tumor resection to an active surveillance strategy. The previous PANDORA-1 (2021) study showed excellent clinical outcomes after a median follow-up of 17 months, where 89% of patients had pNETs without any tumor growth and only 3% of patients had tumor growth leading to a resection. Despite these results, the quality of life (QoL) was decreased at baseline and during follow-up. Furthermore, there was suboptimal adherence to the advised surveillance protocol.

Conference:

Presenting Author: Chen J

Authors: Chen J, Heidsma C, Engelsman A, Nieveen van Dijkum E,

Keywords: neuroendocrine, pancreatic, quality of life, ≤2 cm, non-functional, protocol,

#3045 Reliability and Agreement of Radiological and Pathological Tumor Size in Patients with MEN1-Related Pancreatic Neuroendocrine Tumors: Results from a Population-Based Cohort

Introduction: Pancreatic neuroendocrine tumors (pNETs) are the most lethal manifestation in patients with multiple endocrine neoplasia type 1 (MEN1). Tumor size is still regarded as the main prognostic factor and therefore used for surgical decision making.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: van Beek D

Authors: van Beek D, Verkooijen H, Bonsing B, van Eijck C, van Goor H,

Keywords: Multiple endocrine neoplasia type 1, pancreatic neuroendocrine tumor, reliability, agreement, computed tomography, magnetic resonance imaging, endoscopic ultrasonography, pathology,